Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer

Takenaka, Tomoyoshi; Inamasu, Eiko; Yoshida, Tsukihisa; Toyokawa, Gouji; Nosaki, Kaname; Hirai, Fumihiko; Yamaguchi, Masafumi; Seto, Takashi; Takenoyama, Mitsuhiro; Ichinose, Yukito

doi:10.1007/s00595-015-1200-9

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An explanation for this is likely the result of several factors including a high relative proportion of epithelial growth factor receptor ( EGFR )-mutation positive lung tumors for targeted therapies, the standardized long-term surveillance of lung cancer survivors, and the coordinated efforts on a national level to monitor and improve cancer care in Japan. 52,53 …”

Section: Resultsmentioning

confidence: 99%

The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics

Cheng

Cramb

Baade

et al. 2016

Journal of Thoracic Oncology

508

392

View full text Add to dashboard Cite

Introduction We aim to update global lung cancer epidemiology and describe changing trends and disparities. Methods We presented country-specific incidence and mortality from GLOBOCAN 2012, by region and socioeconomic factors via the Human Development Index (HDI). Between- and within-country incidence by histological type was analyzed from Cancer Incidence in Five Continents Volume X (IARC). Trend analyses including the IARC data, cancer registries, and the WHO Mortality database were conducted using Joinpoint regression. Survival was compared between and within countries, and by histology. Results In 2012, there were 1.82 and 1.59 million new cases and deaths of lung cancer worldwide, respectively. Incidence was highest in very high HDI countries and lowest in low HDI countries (42.2 vs. 7.9/100,000 for males and 21.8 vs. 3.1/100,000 for females, respectively). In most countries with a very high HDI, as male incidence decreased gradually (ranging from −0.3% in Spain to −2.5% in the USA each year), female incidence continued to increase (by 1.4% each year in Australia to 6.1% in recent years in Spain). While histology varied between countries, adenocarcinoma was more common than squamous cell carcinoma, particularly among females (e.g., in Chinese females, the adenocarcinoma-to-squamous cell carcinoma ratio=6.6). Five-year relative survival varied from 2% (Libya) to 30% (Japan), with substantial within-country differences. Conclusion Lung cancer will continue to be a major health problem well through the first half of this century. Preventive strategies, particularly tobacco control, tailored to populations at highest risk are key to reduce the global burden of lung cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics

Cheng

Cramb

Baade

et al. 2016

Journal of Thoracic Oncology

508

392

View full text Add to dashboard Cite

show abstract

“…Theoretically, additional survival advantage should be expected in elderly population having GGO lesions and undergoing sublobar resection. Evidences are accumulating that sublobar resections (segmentectomy or big wedge resection) are oncologically equivalent to standard lobectomy for small (≤2 cm) less invasive histology (Adenocarcinoma in situ or Minimal Invasive Adenocarcinoma) appearing as GGO on CT scan [20,21,22,23].…”

Section: Discussionmentioning

confidence: 99%

Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate choice in elderly patients?

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Genetic sequencing of the initial tumor specimen is often used to determine therapy at recurrence although tumor spatial heterogeneity may lead to poorer efficacy to targeted therapy ( 29 , 30 ). In our study, through the analysis of matched primary and post-operative recurrence in 45 patients, we observed two key findings: first, temporal genetic heterogeneity occurred relatively commonly between the primary and post-operative recurrent NSCLC tumors; Second, temporal heterogeneity might influence the therapeutic efficacy of first-line EGFR TKI treatment at relapse.…”

Section: Discussionmentioning

confidence: 99%

Temporal genomic heterogeneity guiding individualized therapy in recurrent non-small cell lung cancer

et al. 2023

View full text Add to dashboard Cite

IntroductionDespite the benefit of adjuvant systemic therapy for patients with resected non-small cell lung cancer (NSCLC), the risk of postoperative recurrence remains high. Our objective was to characterize temporal genetic heterogeneity between primary resected and recurrent tumors, and its impact on treatment outcomes.MethodsIn this study, next-generation sequencing (NGS) testing was performed on tissue specimens and circulating tumor DNA (ctDNA) collected at postoperative recurrence, and results were compared to the genotypes of initial surgical specimens.ResultsOf forty-five patients with matched primary and post-operative recurrent tumors, EGFR status switched in 17 patients (37.8%) at post-operative recurrence and 28 patients (62.2%) had no genotype change (17 mutant, 11 wild-type). Based on the changes of EGFR status, patients were divided into 4 groups. Following subsequent treatment with EGFR TKI o chemotherapy: In group A, with sustained sensitive mutation, the percentage achieving partial response (PR) was the highest, at 72.2%, the median progression-free survival (PFS) was 17 months, and the median overall survival (OS) was 44.0 months respectively; In group B, with genotype changed from wild-type to mutant, 50% achieved PR, PFS was 10 months, and OS was 35 months; In group C, in which mutant status shifted to wild-type or new co-mutation emerged, the percentage achieving PR was 30%, PFS was 9 months, and OS was 35 months. In group D, with sustained wild type, the percentage achieving PR was 27.3%, PFS was 8 months, and OS was 22 months.DiscussionGenotypic shift between paired primary and post-operative recurrent tumors was not infrequent, and this temporal genomic heterogeneity substantially impacted subsequent treatment outcomes.

show abstract

Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer

Abstract: Elderly patients 75 years of age or older in this study achieved satisfactory long-term outcomes.

Cited by 7 publications

References 21 publications

The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics

The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics

Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate choice in elderly patients?

Temporal genomic heterogeneity guiding individualized therapy in recurrent non-small cell lung cancer

Contact Info

Product

Resources

About